@article{article, title  = {{Validity of proportional hazards (PH) Weibull models for analyzing progression free survival (PFS) and overall survival (OS) in patients with trastuzumab (TZ)-refractory ERBB2+(HER2+) metastatic breast cancer (MBC) receiving lapatinib plus capecitabine (L+C) versus capecitabine only (C-only)}},

 url = {{}},

 year = {{2008}},

 month = {{5}},

 author = {{Sofrygin O and Delea T and Tappenden P and Karnon J and Amonkar MM and Walker M}},

 volume = {{11}},

 journal = {{VALUE HEALTH}},

 issue = {{3}},

 pages = {{A57-A57}},

 note = {{Accessed on 2025/04/05}}}